Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurovirol ; 25(4): 475-479, 2019 08.
Article in English | MEDLINE | ID: mdl-31028690

ABSTRACT

There are only few documented cases of progressive multifocal leukoencephalopathy (PML) in Africa. Whether this is caused by a lack of JC virus (JCV) spread or alteration in the JCV genome is unknown. We characterized the clinical presentation, laboratory findings, and JCV regulatory region (RR) pattern of the first documented PML cases in Zambia as well as JCV seroprevalence among HIV+ and HIV- Zambians. We identified PML patients with positive JCV DNA PCR in their cerebrospinal fluid (CSF) among subjects enrolled in an ongoing tuberculous meningitis study from 2014 to 2016 in Lusaka. JCV regulatory region was further characterized by duplex PCR in patients' urine and CSF. Of 440 HIV+ patients, 14 (3%) had detectable JCV DNA in their CSF (age 18-50; CD4+ T cells counts 15-155 × 106/µl) vs 0/60 HIV- patients. The main clinical manifestations included altered mental status and impaired consciousness consistent with advanced PML. While prototype JCV was identified by duplex PCR assay in the CSF samples of all 14 PML patients, only archetype JCV was detected in their urine. All PML Zambian patients tested were seropositive for JCV compared to 46% in a control group of HIV+ and HIV- Zambian patients without PML. PML occurs among HIV-infected individuals in Zambia and is caused by CNS infection with prototype JCV, while archetype JCV strains are present in their urine. JCV seroprevalence is comparable in Zambia and the USA, and PML should be included in the differential diagnosis of immunosuppressed individuals presenting with neurological dysfunction in Zambia.


Subject(s)
DNA, Viral/genetics , Henipavirus Infections/diagnosis , JC Virus/genetics , Leukoencephalopathy, Progressive Multifocal/diagnosis , Tuberculosis, Meningeal/diagnosis , Adolescent , Adult , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/virology , Case-Control Studies , Coinfection , DNA, Viral/cerebrospinal fluid , DNA, Viral/urine , Female , Genotype , HIV/drug effects , HIV/genetics , HIV/isolation & purification , Henipavirus Infections/cerebrospinal fluid , Henipavirus Infections/drug therapy , Henipavirus Infections/virology , Humans , JC Virus/drug effects , JC Virus/isolation & purification , Leukoencephalopathy, Progressive Multifocal/cerebrospinal fluid , Leukoencephalopathy, Progressive Multifocal/drug therapy , Leukoencephalopathy, Progressive Multifocal/virology , Male , Middle Aged , Seroepidemiologic Studies , Tuberculosis, Meningeal/cerebrospinal fluid , Tuberculosis, Meningeal/drug therapy , Tuberculosis, Meningeal/virology , Zambia
2.
Article in English | MEDLINE | ID: mdl-22782307

ABSTRACT

Until the Nipah outbreak in Malaysia in 1999, knowledge of human infections with the henipaviruses was limited to the small number of cases associated with the emergence of Hendra virus in Australia in 1994. The Nipah outbreak in Malaysia alerted the global public health community to the severe pathogenic potential and widespread distribution of these unique paramyxoviruses. This chapter briefly describes the initial discovery of Nipah virus and the challenges encountered during the initial identification and characterisation of the aetiological agent responsible for the outbreak of febrile encephalitis. The initial attempts to isolate Nipah virus from the bat reservoir host are also described.


Subject(s)
Disease Outbreaks , Disease Reservoirs/veterinary , Encephalitis, Viral/diagnosis , Encephalitis, Viral/epidemiology , Henipavirus Infections/diagnosis , Henipavirus Infections/epidemiology , Nipah Virus/isolation & purification , Animals , Australia/epidemiology , Chiroptera/virology , Chlorocebus aethiops , Encephalitis, Viral/cerebrospinal fluid , Encephalitis, Viral/virology , Hendra Virus/isolation & purification , Hendra Virus/pathogenicity , Henipavirus Infections/cerebrospinal fluid , Henipavirus Infections/virology , Humans , Malaysia/epidemiology , Nipah Virus/pathogenicity , Vero Cells
3.
Curr Top Microbiol Immunol ; 359: 179-96, 2012.
Article in English | MEDLINE | ID: mdl-22481141

ABSTRACT

Since the last major review on diagnosis of henipavirus infection about a decade ago, significant progress has been made in many different areas of test development, especially in the development of molecular tests using real-time PCR and many novel serological test platforms. In addition to provide an updated review of the current test capabilities, this review also identifies key future challenges in henipavirus diagnosis.


Subject(s)
Hendra Virus/isolation & purification , Henipavirus Infections/diagnosis , Nipah Virus/isolation & purification , Animals , Cell Line , Enzyme-Linked Immunosorbent Assay , Hendra Virus/genetics , Hendra Virus/pathogenicity , Henipavirus Infections/blood , Henipavirus Infections/cerebrospinal fluid , Henipavirus Infections/virology , Humans , Immunohistochemistry , Microscopy, Electron , Molecular Typing , Neutralization Tests , Nipah Virus/genetics , Nipah Virus/pathogenicity , Real-Time Polymerase Chain Reaction
4.
Ann Neurol ; 62(3): 235-42, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17696217

ABSTRACT

OBJECTIVE: Nipah virus (NiV) is an emerging zoonosis. Central nervous system disease frequently results in high case-fatality. Long-term neurological assessments of survivors are limited. We assessed long-term neurologic and functional outcomes of 22 patients surviving NiV illness in Bangladesh. METHODS: During August 2005 and May 2006, we administered a questionnaire on persistent symptoms and functional difficulties to 22 previously identified NiV infection survivors. We performed neurologic evaluations and brain magnetic resonance imaging (MRI). RESULTS: Twelve (55%) subjects were male; median age was 14.5 years (range 6-50). Seventeen (77%) survived encephalitis, and 5 survived febrile illness. All but 1 subject had disabling fatigue, with a median duration of 5 months (range, 8 days-8 months). Seven encephalitis patients (32% overall), but none with febrile illness had persistent neurologic dysfunction, including static encephalopathy (n = 4), ocular motor palsies (2), cervical dystonia (2), focal weakness (2), and facial paralysis (1). Four cases had delayed-onset neurologic abnormalities months after acute illness. Behavioral abnormalities were reported by caregivers of over 50% of subjects under age 16. MRI abnormalities were present in 15, and included multifocal hyperintensities, cerebral atrophy, and confluent cortical and subcortical signal changes. INTERPRETATION: Although delayed progression to neurologic illness following Nipah fever was not observed, persistent fatigue and functional impairment was frequent. Neurologic sequelae were frequent following Nipah encephalitis. Neurologic dysfunction may persist for years after acute infection, and new neurologic dysfunction may develop after acute illness. Survivors of NiV infection may experience substantial long-term neurologic and functional morbidity.


Subject(s)
Henipavirus Infections/pathology , Henipavirus Infections/physiopathology , Nipah Virus , Adolescent , Adult , Bangladesh , Brain/pathology , Child, Preschool , Disease Progression , Electroencephalography , Encephalitis/pathology , Encephalitis/physiopathology , Enzyme-Linked Immunosorbent Assay , Fatigue/etiology , Female , Follow-Up Studies , Henipavirus Infections/cerebrospinal fluid , Humans , Immunoglobulin G/analysis , Magnetic Resonance Imaging , Male , Middle Aged , Muscle Weakness/etiology , Nervous System Diseases/etiology , Nervous System Diseases/pathology , Nervous System Diseases/physiopathology , Neurologic Examination , Recurrence , Reverse Transcriptase Polymerase Chain Reaction , Surveys and Questionnaires , Survivors
SELECTION OF CITATIONS
SEARCH DETAIL
...